Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 585-593, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (32)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bon, G. G.
Right arrow Articles by Vermorken, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bon, G. G.
Right arrow Articles by Vermorken, J. B.
Related Collections
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 1997;43:585-593.)
© 1997 American Association for Clinical Chemistry, Inc.

Articles

Clinical and technical evaluation of ACSTMBR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays

Gijsbert G. Bon1, Silvia von Mensdorff-Pouilly1, Peter Kenemans1,a, Gerard J. van Kamp2, Rob A. Verstraeten1, Jo Hilgers1, Sybren Meijer3 and Jan B. Vermorken4

Departments of
1 Obstetrics and Gynaecology,
2 Clinical Chemistry,
3 Surgery, and
4 Medical Oncology, Academic Hospital Vrije Universiteit, De Boelelaan 1117, NL-1081 HV Amsterdam, The Netherlands.
a Author for correspondence. Fax +31-20-4444811; e-mail kenemans{at}azvu.nl

The mucin glycoprotein-detecting assay CA 15-3 is a valuable tool for monitoring the course of disease in breast cancer patients. Assays of CA 15-3 are based on the use of two MAbs to polymorphic epithelial mucin (PEM). We evaluated the technical and clinical performance of the Chiron ACSTM BR, an automated competitive chemiluminescence assay using a single MAb, B27.29, and compared the assay's results with those of the Centocor CA 15-3 RIA, the Abbott IMx CA 15-3, and the Boehringer Mannheim Enzymun-Test CA 15-3. The study population consisted of 253 healthy women, 66 patients with benign breast disease, 168 breast cancer patients, and 76 patients with other carcinomas. In the technical evaluation, we assessed the precision and linearity on dilution of the ACS BR assay. Cutoff values (upper limits of values seen in healthy subjects) were determined for all four assays. Agreement between the assays was studied by linear regression analysis. The ACS BR assay gave within- and between-assay CVs of 2.2% and 3.9%, respectively. Three samples from healthy women gave discordant values by ACS BR and were not included in the calculations. All four assays exhibit a highly similar pattern when monitoring breast cancer disease; the closest agreement of values was obtained between ACS BR and Centocor CA 15-3. We conclude that the ACS BR assay is a fast and reliable immunoassay for measuring PEM in serum. Although it detects a slightly different epitope on the PEM molecule than is targeted in other assays, for cancer serum samples it agreed better with the original Centocor CA 15-3 assay than did the other two CA 15-3 assays tested.


Key Words: indexing terms: polymorphic epithelial mucin • mucin glycoproteins • tumor markers • chemiluminescence immunoassay • monoclonal antibodies • method comparisons • ROC curve analysis




The following articles in journals at HighWire Press have cited this article:


Home page
 Lab MedHome page
B. Handy
The Clinical Utility of Tumor Markers
Lab Med, February 1, 2009; 40(2): 99 - 103.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. P. Treon, P. Maimonis, D. Bua, G. Young, N. Raje, J. Mollick, D. Chauhan, Y.-T. Tai, T. Hideshima, Y. Shima, et al.
Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma
Blood, November 1, 2000; 96(9): 3147 - 3153.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. von Mensdorff-Pouilly, A. A. Verstraeten, P. Kenemans, F. G. M. Snijdewint, A. Kok, G. J. Van Kamp, M. A. Paul, P. J. Van Diest, S. Meijer, and J. Hilgers
Survival in Early Breast Cancer Patients Is Favorably Influenced by a Natural Humoral Immune Response to Polymorphic Epithelial Mucin
J. Clin. Oncol., February 1, 2000; 18(3): 574 - 574.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. Gion, R. Mione, A. E. Leon, and R. Dittadi
Comparison of the Diagnostic Accuracy of CA27.29 and CA15.3 in Primary Breast Cancer
Clin. Chem., May 1, 1999; 45(5): 630 - 637.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.